Assessment of serum vitamin D levels in Egyptian children with beta-thalassemia major

Abdelmotaleb, Ghada S.; Behairy, Ola Galal; Azim, Khalid Eid Abd El; El-Hassib, Dalia Mohamed Abd; Hemeda, Tasbeh Mohamed

doi:10.1186/s43054-021-00066-y

Cited by 5 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast to our findings, in a previous study [22] on 55 Egyptian β-thalassemia children aged (5-17 years), the patients of the study had significantly higher serum phosphorus and ALP levels, and serum calcium was significantly lower than the control group. The results in these studies are in agreement with Karim et al [23], who showed that β-thalassemia patients had shown significantly low serum calcium levels in comparison with the controls. Also, Hagag et al [24] found that serum calcium levels are significantly lower in the patients group, and serum phosphorus and ALP levels are significantly higher.…”

Section: Discussionsupporting

confidence: 92%

Association of Bone Disorder and Gene Polymorphism of PPAR-γ Pro12 Ala in Egyptian Children with β-Thalassemia

Hamied,

Ahmed,

Eldahshan

et al. 2023

Thalassemia Reports

View full text Add to dashboard Cite

β-thalassemia is a genetic disorder affecting chromosome 16, inherited from one or both parents. In spite of the improved treatment of the hematological disorder and its complications, β-thalassemic patients still exhibit an imbalance in bone mineral turnover, resulting in diminished bone mineral density (BMD), more evident in the lumbar spine. The purpose of this study was to investigate the association between genetic polymorphism of the PPAR-γ gene and the presence of osteopenia or osteoporosis in children with β-thalassemia. This case–control study was conducted on 50 children with β-thalassemia from the pediatric hematology unit of Beni-Suef University Hospital, including 50 healthy children as the control group. The age range was 8 to 18 years. Samples of patients and control subjects were analyzed for the presence of polymorphisms of the PPAR-γ gene and other blood labs. An assay of BMD measure using dual-energy X-ray absorptiometry (DXA) was performed to investigate osteopenia or osteoporosis. Statistical analysis was used to investigate the relationship between the risk of osteopenia or osteoporosis and the presence of PPAR-γ Pro12Ala gene polymorphism. Eighteen (eleven males and seven females) of fifty patients (representing 36% of the patients group) have osteopenia with low bone mineral density (Z-score is −1 or less than 1). There was no statistically significant difference between BMD measurements in males and females. By comparing the frequency of 12 Ala gene polymorphisms between the patient group and the control group, we found that no statistically significant difference was detected. The BMD values were not significantly different between the groups of PPAR-γ Pro12Ala gene polymorphism. In conclusion, decreased BMD levels are frequent in β-thalassemia patients. PPAR-γ Pro12Ala gene polymorphism is not common in Egyptian patients with β-thalassemia. No significant relationship was found between the PPAR-γ Pro12Ala gene polymorphism and low BMD levels or osteopenia in Egyptian β-thalassemia patients. However, further studies on a larger population of Egyptian patients are needed to confirm this finding.

show abstract

Section: Discussionsupporting

confidence: 92%

Association of Bone Disorder and Gene Polymorphism of PPAR-γ Pro12 Ala in Egyptian Children with β-Thalassemia

Hamied,

Ahmed,

Eldahshan

et al. 2023

Thalassemia Reports

View full text Add to dashboard Cite

show abstract

“…The results of the current study agree with the findings of Jumaa (21) , who showed in his study a low level of vitamin D in patients with hemolytic anemia compared to healthy group. As hemolytic anemia patients are at risk of a number of complications, including poor growth, endocrinopathy, and metabolic abnormalities (22)(23)(24)(25) . Vitamin D is necessary for calcium homeostasis and skeletal mineralization.…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Steroid Hormones Level, Vitamin D3, K and Some Minerals in The Sera of Patients Infected with Glucose-6-Phosphate Dehydrogenase Deficiency

Latif

Shaker

2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: The deficiency of glucose-6-phosphate dehydrogenase enzyme (Glucose-6-phosphate dehydrogenase G6PD) is one of the genetic blood diseases. It is a disease related to the sex of the newborn, meaning that this disease is genetic disease linked to sex, and usually affects males more than females.Objective: The study aimed to evaluate the activity of some fatty acids and glucose-6-phosphate dehydrogenase enzyme in the blood of glucose-6-phosphate dehydrogenase deficient patients. Subjects and methods:The study was a group of 118 blood samples, 58 samples from healthy people (control), distributed as 34 males and 24 females in addition to 60 patients with glucose-6-phosphate dehydrogenase deficiency. The subjects were collected from the Outpatient Clinics in Baghdad City and Al-Dhuluiya district, Salah Al-Din district between 20/11/ 2020/ and 15/3/2021. The current study evaluated glucose-6-phosphate dehydrogenase enzyme activity, steroid hormones (Testosterone and dihydrotestosterone), Vit. D3, K, Ca, Cu and Zn in the serum of studied subjects. Results: There was a significant decrease in G-6-P-D in the blood serum of patients compared to the healthy group. Also, the results showed significant decrease in testosterone, DHEA, vit D3 and vit. k in the blood serum of patients compared to the healthy group. Additionally, the results showed that there was significant decrease in Zn in patients' blood serum compared to the healthy group. However, the results revealed an increase in Cu in the blood serum of patients when compared to the healthy group. Furthermore, the results revealed that there was no significant change in Ca between patients and healthy people.

show abstract

“…This result is consistent with other studies showing high rates of vitamin D deficiency in thalassemia patients. 21,22 This highlights the importance of monitoring vitamin D levels in this patient population. Factors associated with decreased vitamin D levels include avoidance of sun exposure, poor nutrition, 21 inadequate physical activity, and defective hydroxylation of vitamin D due to hepatic dysfunction.…”

mentioning

confidence: 99%

“…21,22 This highlights the importance of monitoring vitamin D levels in this patient population. Factors associated with decreased vitamin D levels include avoidance of sun exposure, poor nutrition, 21 inadequate physical activity, and defective hydroxylation of vitamin D due to hepatic dysfunction. 23 Health education, food fortification policies, and early detection monitoring are necessary to mitigate the risk of vitamin D deficiency and promote bone health and growth in thalassemia patients.…”

mentioning

confidence: 99%

“…23 Health education, food fortification policies, and early detection monitoring are necessary to mitigate the risk of vitamin D deficiency and promote bone health and growth in thalassemia patients. 21 Growth failure in thalassemia may be attributed to economic status 24 and clinical factors such as the degree of chronic hypoxia, iron overload, several micronutrient deficiencies, and parental height. 25,26 In this study, the prevalence of growth failure was 15%, consistent with other studies (13%-21%), 10,12 with the failure more pronounced among our patients with NDHbH.…”

mentioning

confidence: 99%

See 1 more Smart Citation

HEMOGLOBIN H DISEASE AND GROWTH: A COMPARATIVE STUDY OF DHbH AND NDHbH PATIENTS

Hunnuan,

SAnpakit,

Lertbannaphong

et al. 2023

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Background: Hemoglobin H disease (HbH), a hemoglobinopathy resulting from abnormal alpha globin genes, is classified into two categories: deletional HbH (DHbH) and non-deletional HbH (NDHbH). The alpha-mutation genotypes exhibit a range of clinical anemias, which differentially impact patient growth. Objectives: This retrospective study assessed the growth of HbH patients at Siriraj Hospital, Mahidol University. Methods: Patients diagnosed with HbH between January 2005 and April 2021 were analyzed using growth standard scores of the Thai Society for Pediatric Endocrinology (2022 version) and BMI-for-age Z scores of the World Health Organization. Growth failure was defined as a patient’s height for age exceeding two standard deviations below the mean. Results: Of the 145 HbH patients, 75 (51.7%) had NDHbH, with --SEA/αCSα being the most common genotype (70 patients; 93.3%). The mean baseline hemoglobin level was significantly lower in NDHbH patients than in DHbH patients (8.16 ± 0.93 g/dL vs. 9.51 ± 0.68 g/dL; P < 0.001). Splenomegaly and growth failure prevalences were higher in NDHbH patients (37.3% vs. 0%, with P < 0.001, and 22.7% vs. 8.6%, with P = 0.020, respectively). Multivariable analysis revealed that splenomegaly > 3 cm was associated with growth failure (OR = 4.28; 95% CI, 1.19–15.39; P = 0.026). Conclusions: NDHbH patients exhibited lower hemoglobin levels and more pronounced splenomegaly than DHbH patients. Growth failure can occur in both HbH types but appears more prevalent in NDHbH. Close monitoring of growth velocity is essential, and early treatment interventions may be required to prevent growth failure.

show abstract

Assessment of serum vitamin D levels in Egyptian children with beta-thalassemia major

Cited by 5 publications

References 23 publications

Association of Bone Disorder and Gene Polymorphism of PPAR-γ Pro12 Ala in Egyptian Children with β-Thalassemia

Association of Bone Disorder and Gene Polymorphism of PPAR-γ Pro12 Ala in Egyptian Children with β-Thalassemia

Evaluation of Steroid Hormones Level, Vitamin D3, K and Some Minerals in The Sera of Patients Infected with Glucose-6-Phosphate Dehydrogenase Deficiency

HEMOGLOBIN H DISEASE AND GROWTH: A COMPARATIVE STUDY OF DHbH AND NDHbH PATIENTS

Contact Info

Product

Resources

About